Application of peripheral blood mononuclear cells circGSAP
A nuclear cell and peripheral blood technology, applied in the application field of peripheral blood mononuclear cell circGSAP
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0021] ① Research population
[0022] In May 2009, 6 newly admitted IPAH patients and 6 healthy controls were recruited as the discovery group. Sixty IPAH patients and 30 healthy controls were selected as the validation group. IPAH was diagnosed in both groups according to the then-current guidelines of the European Society of Cardiology and the European Respiratory Society. Specifically, the inclusion criteria for the two groups of patients were mPAP ≥ 25 mmHg, mPAWP ≤ 15 mmHg, and PVR > 3WU, and patients who excluded other causes of PAH. Patients with established etiologies associated with PAH, such as connective tissue disease and congenital heart disease, and patients with other pulmonary artery obstruction such as pulmonary hypertension due to left heart disease and chronic thromboembolic pulmonary hypertension were excluded. We also excluded patients with acute or chronic diseases that might affect plasma levels (ie, acute or chronic infections, chronic autoimmune dise...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com